Skip to main content
Hester Biosciences Ltd logo

Hester Biosciences Ltd — Investor Relations & Filings

Ticker · HESTERBIO ISIN · INE782E01017 LEI · 984500836B9EB1DC4935 BSE.NS Manufacturing
Open in API
Filings indexed 672 across all filing types
Latest filing 2024-02-02 Regulatory Filings
Country IN India
Listing BSE.NS HESTERBIO

About Hester Biosciences Ltd

https://www.hester.in/

Hester Biosciences Ltd specializes in the development, manufacturing, and marketing of animal healthcare products. The company primarily focuses on two segments: poultry healthcare and livestock healthcare. Its extensive product portfolio includes a wide range of live and inactivated vaccines, as well as health products such as therapeutics, herbal supplements, and disinfectants. Hester is recognized for its significant contributions to global animal disease control programs, particularly in the eradication of Peste des Petits Ruminants (PPR) and Brucellosis. The company operates advanced manufacturing facilities and maintains a robust distribution network to serve domestic and international markets. By leveraging research and development, Hester provides diagnostic services and technical support to enhance animal productivity and welfare. Its commitment to quality and innovation has established it as a key provider of biologicals and health solutions for the veterinary sector.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Regulatory Filings
2024-02-02 English
Outcome of Board Meeting
Regulatory Filings
2024-02-02 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification to stock exchanges about an upcoming earnings conference call scheduled for February 2, 2024, following the announcement of unaudited financial results for the quarter and nine months ended December 31, 2023. It includes details for joining the call and contact information but does not contain the actual financial results or a transcript of the call. The document length is short (2169 characters) and serves as an announcement rather than the call transcript itself. Therefore, it should be classified as a Call Transcript (CT) related announcement, but since it is only an intimation of the call and not the transcript, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about the call. However, given the specific category for Call Transcript (CT) is for the full transcript, and this is only an intimation, the best fit is Regulatory Filings (RNS).
2024-01-27 English
Board Meeting — HESTER BIOSCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 02-Feb-2024 to inter-alia consider and approve the Unaudited Financial results of the Company fo…
Regulatory Filings
2024-01-24 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a short notice informing stock exchanges about an upcoming Board Meeting scheduled to consider unaudited financial results for the quarter and nine months ended 31 December 2023. It is an intimation of a meeting date and agenda, not the financial results themselves or any detailed report. The document length is only 1068 characters, indicating it is a brief announcement. According to the rules, such notices about board meetings to consider financial results fall under Board/Management Information (MANG).
2024-01-24 English
Updates
Regulatory Filings Classification · 95% confidence The document is a confirmation certificate addressed to stock exchanges regarding securities dematerialised/rematerialised during the quarter ended 31 December 2023. It references compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, and includes a certificate from the Registrar and Share Transfer Agent confirming the dematerialisation process. The document is short (2814 characters) and serves as a regulatory compliance confirmation rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for compliance confirmations and miscellaneous regulatory documents that do not fit other specific categories.
2024-01-08 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.